During the past decade, Keck Medicine of USC- Division of Rheumatology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Keck Medicine of USC- Division of Rheumatology" #1 collaborator was "Gilead Sciences" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Keck Medicine of USC- Division of Rheumatology" are "Rhematoid Arthritis" (1 trials) and "Rheumatoid Arthritis" (1 trials). Many other conditions were trialed in "Keck Medicine of USC- Division of Rheumatology" in a lesser frequency.

Most popular intervention types in "Keck Medicine of USC- Division of Rheumatology" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Adalimumab with methotrexate" (1 trials), "Filgotinib" (1 trials), "Placebo to match filgotinib" (1 trials), "Tofacitinib with methotrexate" (1 trials) and "Tofacitinib without methotrexate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Keck Medicine of USC- Division of Rheumatology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Keck Medicine of USC- Division of Rheumatology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Keck Medicine of USC- Division of Rheumatology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Keck Medicine of USC- Division of Rheumatology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".